论文部分内容阅读
越来越多的研究证实，非小细胞肺癌(NSCLC)中存在可导致肿瘤发生与发展的驱动基因突变，包括EGFR、ALK、ROS1、KRAS、c-MET、HER2、RET、NTRK、PIK3A等，晚期NSCLC患者的治疗模式已经从基于组织病理分型的传统化疗、放疗，发展到基于分子病理分型、个体化的分子靶向治疗模式。分子靶向治疗相较传统治疗方式显著延长患者生存时间，改善生存质量，目前已成为驱动基因阳性晚期NSCLC患者的标准一线治疗方案，改变了晚期NSCLC的治疗模式。本文针对NSCLC驱动基因及最新研发的靶向药物阐述NSCLC分子靶向治疗现状与研究进展。“,”More and more non-small cell lung cancer (NSCLC) have been confirmed to have driver gene mutations which lead to tumor development and progression, including epithelial growth factor receptor (EGFR, ALK, ROS1, KRAS, c-MET, HER2, RET, NTRK, PIK3A, etc). The treatment mode of advanced NSCLC patients has evolved from traditional chemotherapy and radiotherapy based on histopathological classification to personalized targeted therapy based on molecular genetic diagnosis, which significantly improved the outcome of disease and the quality of life.Targeted therapy is becoming the standard first-line therapeutic scheme for the treatment of NSCLC harboring driver genes.This article reviews the driver genes found in NSCLC and the development of novel compounds targeting these driver genes.